Literature DB >> 2287938

Pyramidical model of schizophrenia.

S R Kay1, S Sevy.   

Abstract

Research and treatment of schizophrenia have been impeded by its heterogeneity and the lack of well-standardized methods for a comprehensive assessment of symptoms, including positive and negative dimensions. To study symptom profiles, therefore, we standardized and administered a well-operationalized 30-item psychiatric symptom scale to 240 schizophrenic inpatients. Principal component analysis suggested a pyramidlike triangular model of uncorrelated but nonexclusive syndromes that encompassed the spectrum of psychopathology. Negative, positive, and depressive features constituted divergent points of a triangular base, and excitement made up a separate vertical axis. Paired syndromes could account for symptoms of the paranoid (positive-depressive), disorganized (positive-negative), and catatonic (negative-depressive) diagnostic subtypes. The transversal positions in this model suggested polarized dimensions in schizophrenia, including a prognostic axis (depression-cognitive dysfunction). The findings imply that (1) negative and positive syndromes show factorial validity and distinction from depression but, alone, are insufficient to accommodate the full diversity of symptoms; (2) schizophrenic subtypes derive from a hybrid between unrelated but co-occurring dimensions that may define the fundamental elements of psychopathology; and (3) the pyramidical model is of heuristic value. The results help to clarify the heterogeneity of schizophrenia and to illuminate the path toward syndrome-specific treatments.

Entities:  

Mesh:

Year:  1990        PMID: 2287938     DOI: 10.1093/schbul/16.3.537

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  65 in total

Review 1.  Symptom dimensions in the course of childhood-onset schizophrenia.

Authors:  D Bunk; C Eggers; M Klapal
Journal:  Eur Child Adolesc Psychiatry       Date:  1999       Impact factor: 4.785

Review 2.  Categorical vs dimensional classifications of psychotic disorders.

Authors:  Melissa Potuzak; Caitlin Ravichandran; Kathryn E Lewandowski; Dost Ongür; Bruce M Cohen
Journal:  Compr Psychiatry       Date:  2012-06-07       Impact factor: 3.735

Review 3.  Positive-negative symptom assessment in schizophrenia: psychometric issues and scale comparison.

Authors:  S R Kay
Journal:  Psychiatr Q       Date:  1990

Review 4.  Elderly patients with schizophrenia and depression: diagnosis and treatment.

Authors:  Kandi Felmet; Sidney Zisook; John W Kasckow
Journal:  Clin Schizophr Relat Psychoses       Date:  2011-01

Review 5.  Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research.

Authors:  Julie W Messinger; Fabien Trémeau; Daniel Antonius; Erika Mendelsohn; Vasthie Prudent; Arielle D Stanford; Dolores Malaspina
Journal:  Clin Psychol Rev       Date:  2010-09-18

6.  Symptom dimensions and outcome in schizophrenia.

Authors:  Raimo K R Salokangas
Journal:  World Psychiatry       Date:  2003-10       Impact factor: 49.548

7.  Timing dysfunctions in schizophrenia as measured by a repetitive finger tapping task.

Authors:  Christine A Carroll; Brian F O'Donnell; Anantha Shekhar; William P Hetrick
Journal:  Brain Cogn       Date:  2009-08-06       Impact factor: 2.310

8.  Sparse factors for the positive and negative syndrome scale: which symptoms and stage of illness?

Authors:  Ariana Anderson; Marsha Wilcox; Adam Savitz; Hearee Chung; Qingqin Li; Giacomo Salvadore; Dai Wang; Isaac Nuamah; Steven P Riese; Robert M Bilder
Journal:  Psychiatry Res       Date:  2015-01-06       Impact factor: 3.222

Review 9.  Co-occurring depressive symptoms in the older patient with schizophrenia.

Authors:  John W Kasckow; Sidney Zisook
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

10.  EEG alpha coherence and psychopathological dimensions of schizophrenia.

Authors:  John P John; Sumant Khanna; N Pradhan; C R Mukundan
Journal:  Indian J Psychiatry       Date:  2002-04       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.